DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers

First-in-human dose escalation results from phase 1/2 study of DS-7300, Daiichi Sankyo’s fourth DXd ADC in clinical development, highlighted in Proffered Paper session at ESMO Dose expansion to enroll three cohorts of patients with metastatic small...

Full "IntellAsia: Resources" article